ocular involvement; ocular damage is not frequently reported in the literature. 1, 2 In more than half of the patients with aHUS, it is possible to identify the complement mutation or the mutation in other molecules leading to abnormal complement regulation. However, genetic study is not necessary for diagnosis and initiation of therapy. However genetic studies should be performed to establish prognosis, as some mutations are more aggressive than others. Moreover, genetic study allows more adequate strategy for renal transplantion. 1, 2, 5 Up to 30% of patients have no documented genetic mutation, 4, 6 as it was the case in our patient.
The treatment of choice for aHUS is eculizumab, a humanised monoclonal antibody that blocks the cleavage of the C5 component of complement, thus preventing the release of the anaphylatoxin C5a and the formation of the membrane attack complex C5b-9. This prevents endothelial damage and the generation of thrombotic microangiopathy. 1, 7, 8 As a prerequisite for starting eculizumab, the patient must be vaccinated against meningococcus and start antibiotic prophylaxis directed against meningococcus whilst the vaccine becomes effective. The earlier eculizumab is started in patients with aHUS, the higher the likelihood of recovery and the fewer sequelae. 5, 9 Nonetheless, whilst the diagnosis of aHUS is being established, plasma exchanges can stabilise the patient's haemolytic activity, therefore these should be started early if the clinical picture is one of a thrombotic microangiopathy. It should be kept in mind that blood samples should be obtained for ADAMTS13 activity and autoantibody profile prior to plasma exchange to avoid missing other diagnoses. 1, 5, 7 If the definitive diagnosis is aHUS, treatment should be changed to eculizumab, as long-term plasma therapy has not been shown to change the devastating course of aHUS. 1, 5, 9, 10 In our patient, plasma exchanges were performed initially, achieving control of haemolytic activity; once the diagnosis of aHUS was established, treatment was changed to eculizumab, achieving a good response with no further need for plasma exchange and no further relapses (Fig. 1) . However, the patient was left with the sequela of ESRD. 
Conclusion
Atypical HUS is a rare genetic disease that affects children and adults, characterised by the presence of non-immune microangiopathic haemolytic anaemia, thrombocytopenia and multi-organ damage. The clinical course can be devastating and endanger patients' life and quality of life, leaving them with severe sequelae such as ESRD. Treatment with eculizumab must be started early to halt multi-organ damage and avoid death.
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r e f e r e n c e s We report a case of a woman who experienced vaginal leakage during CAPD and after peritonitis. A 24 year old female patient was diagnosed with end stage renal disease during pregnancy. There was no other etiological factor, but hypertension. Patient was recommended 20 hours of hemodialysis, but she refused and gave birth to a living child on the 38th gestational week. She has been on CAPD for the last 3 months. Since last week she has started to have abdominal pain accompanied with nausea and fever (>38 • C). With these complaints she was referred to our policlinic and her peritoneal fluid cell count was found 4860/mm 3 (95% polymorphonuclear leukocytes). Cultures were obtained and she was admitted to our hospital with the diagnosis of peritonitis. Blood analysis showed leucocytes 9000/mm 3 , hemoglobin: 8.8 g/dl (11.5-16), C-reactive protein: 14.2 mg/dl (0-0.5), sedimentation: 135 mm/hour. Pseudomonas aeruginosa was detected in blood cultures. She was on empiric ceftazidime and cefazolin treatment and treatment was continued because P. aeruginosa was found sensitive to this treatment. Urine culture remained sterile. Patient stated that there is dialysate in her vagina. She was consulted with obstetrics and gynecology regarding any fistulas. A urine catheter was placed and it is understood that origin of dialysate was vagina. Contrast enhanced computerized tomography was done showing a vaginal fistula (Figs. 1 and 2 ). CAPD catheter was removed. Surgical operation was found unnecessary and hemodialysis was started. Patient was discharged after 3 weeks of ant biotherapy. 
